Source: Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis



Rating:

Share or cite this content

Citations should be made in the following way:
A. Matralis (Athens, Greece), T. Karampitsakos (Patras, Greece), O. Papaioannou (Patras, Greece), M. Katsaras (Patras, Greece), F. Sampsonas (Patras, Greece), D. Bouros (Athens, Greece), V. Aidinis (Athens, Greece), A. Tzouvelekis (Patras, Greece). Biosynthesis and implementation of Thyroid Receptor beta (TRß) agonists (thyromimetics) for the treatment of pulmonary fibrosis. 4334

Member's Comments

No comment yet.

Related content which might interest you: Longterm treatment effects of pulmonary hypertantion (PH) in idiopathic pulmonary fibrosis (IPF) patients by endothelin receptor blockade (Bosentan) Source: Eur Respir J 2007; 30: Suppl. 51, 120s Year: 2007 Low Level Laser therapy (LLL) modulates pulmonary immune response and expression of P2X7 purinergic receptor in experimental model of Chronic Obstructive Pulmonary Disorder (COPD) Source: International Congress 2017 – Cigarette smoke and particulate matter: basic science and clinical aspects Year: 2017 C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Aerosol delivery of an immunomodulator (interferon-γ 1b) within mouse lungs Source: International Congress 2015 – Interstitial lung diseases I Year: 2015 IDL-2965: A Selective, highly-potent, oral Integrin antagonist for IPF Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Monitoring of liver function in patients with pulmonary hypertension treated with endothelin receptor antagonists: The value of a novel monitoring system Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Calcium-sensing receptor as a therapeutic target for pulmonary fibrosis Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Role of endothelin B receptor in Th2-induced pulmonary vascular hyperresponsiveness Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Upregulation of Retinoic Acid-Related Orphan Receptor-alpha (RORa) in IPF; a promising therapeutic target Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias Year: 2018 Upregulation of interleukin 13 receptor alpha 2 (IL-13RA2) expression in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 267s Year: 2005 LSC Abstract – Toll-like receptor 4 (TLR4) in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Fractalkine and its receptor (CX3CR1) in primary pulmonary hypertension (PPH) Source: Eur Respir J 2001; 18: Suppl. 33, 2s Year: 2001 LATE-BREAKING ABSTRACT: Role of mir23a and PGC-1 alpha in Pulmonary Hypertension. Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Intracellular accumulation and effects on bile acid transport of endothelin receptor antagonists in sandwich-cultured hepatocytes Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Peroxisome proliferator-activated receptor gamma (PPARγ) protects against pulmonary arterial hypertension (PAH) Source: Eur Respir J 2007; 30: Suppl. 51, 6s Year: 2007 Neuron-derived orphan receptor 1 mediated human pulmonary arterial smooth muscle cells proliferation via cyclin D1 Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014